Nemvaleukin alfa is a Fusion Protein owned by Alkermes, and is involved in 6 clinical trials, of which 1 was completed, and 5 are ongoing.
Nemvaleukin alfa is a fusion protein of interleukin-2 (IL-2) and interleukin-2 (IL-2) receptor alpha. Interleukin-2 (IL-2) is the principal soluble factor which is responsible for the proliferation of activated T cells, and natural killer cells which results in a considerable antitumor response.
The revenue for Nemvaleukin alfa is expected to reach a total of $655m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Nemvaleukin alfa NPV Report.
Nemvaleukin alfa is originated and owned by Alkermes.
Nemvaleukin alfa Overview
Nemvaleukin alfa (ALKS-4230) is under development for the treatment of advanced solid tumors in both refractory and treatment naive patients, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, including non-small cell lung cancer (NSCLC), hepatocellular carcinoma, bile duct cancer (cholangiocarcinoma), extrahepatic bile duct cancer, cervical cancer, endometrial cancer, adenocarcinoma of the gastroesophageal junction, esophageal cancer, recurrent head and neck squamous cell carcinoma, gastric cancer, melanoma, renal cell carcinoma, urothelial carcinoma and microsatellite instability-high cancers including colorectal cancer, triple-negative breast cancer, ovarian carcinoma, chondrosarcoma, pancreatic cancer, rectal cancer, soft tissue sarcomas, lymphoma and patients with metastatic NSCLC whose tumors express low or undetectable PD-L1. The drug candidate is administered as intravenous infusion and subcutaneous route. It is a new biologic entity based on fusion of IL-2 and its receptors (IL-2 receptor alpha). The transactivation and coordinate expression of IL-2 and IL-2R alpha enhances tumor killing T cells. It is developed using Picasso platform which is a fusion protein technology platform that modulates the natural mechanism of action of a biologic and provides safety and tolerability advantages.
Alkermes is a biopharmaceutical company that focuses on the research, development, and commercialization of drugs for the treatment of cancer, neurodegenerative and central nervous system (CNS) diseases. The company’s proprietary products include Aristada and Aristada Initio an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, a once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It also grants licenses under its proprietary technologies to enable third parties to develop, commercialize and manufacture products. Alkermes sells its products primarily to pharmaceutical wholesalers, treatment providers, specialty distributors and pharmacies. The company has global operations. Alkermes is headquartered in Dublin, Ireland.
The company reported revenues of (US Dollars) US$1,173.8 million for the fiscal year ended December 2021 (FY2021), an increase of 13% over FY2020. The operating loss of the company was US$32.3 million in FY2021, compared to an operating loss of US$112.4 million in FY2020. The net loss of the company was US$48.2 million in FY2021, compared to a net loss of US$110.9 million in FY2020. The company reported revenues of US$252.4 million for the third quarter ended September 2022, a decrease of 8.6% over the previous quarter.
Quick View – Nemvaleukin alfa
|Highest Development Stage|